649 filings
6-K
CANF
Can-Fite Biopharma Ltd
25 Apr 24
Current report (foreign)
7:03am
6-K
CANF
Can-Fite Biopharma Ltd
15 Apr 24
A pivotal Phase III trial for advanced liver cancer, approved by FDA & EMA and a MASH Phase IIb are enrolling patients
7:03am
EFFECT
CANF
Can-Fite Biopharma Ltd
10 Apr 24
Notice of effectiveness
12:15am
S-8
CANF
Can-Fite Biopharma Ltd
5 Apr 24
Registration of securities for employees
4:15pm
POS AM
CANF
Can-Fite Biopharma Ltd
5 Apr 24
Prospectus update (post-effective amendment)
4:15pm
6-K
iiwwgy
3 Apr 24
Report of Foreign Private Issuer
7:07am
6-K
c6i5rcnz5q3 6q2mgh
28 Mar 24
Can-Fite Reports 2023 Financial Results and Clinical Update
7:05am
6-K
pyxcfhwi56a4e69b
11 Mar 24
Report of Foreign Private Issuer
7:27am
6-K
bu35z2on
28 Feb 24
Patent has already been issued in other major markets including the U.S., EU, Japan and China
7:06am
6-K
843xx
30 Jan 24
Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication
7:24am
6-K
haz0j01z80nb
29 Jan 24
Piclidenoson is a small molecule safe oral drug suitable for the chronic treatment of patients who suffer from moderate to severe plaque psoriasis
7:05am
EFFECT
xie3n68pt 1238m
8 Jan 24
Notice of effectiveness
12:15am
CORRESP
eqpss7 3e2
3 Jan 24
Correspondence with SEC
12:00am
F-3/A
nbjbn8ky
28 Dec 23
Shelf registration (foreign) (amended)
4:16pm
6-K
ta09k k3m748gin
20 Dec 23
Robust support for Namodenoson’s potential development as an anti-obesity drug, a projected $100 billion market by 2030
7:09am
6-K
igbky7 h69s1n4
18 Dec 23
Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan
7:07am
F-3
wm5sitdz46l udw9
12 Dec 23
Shelf registration (foreign)
4:15pm
6-K
bh0wtj3 toli7zxz7
4 Dec 23
Report of Foreign Private Issuer
7:05am
6-K
8q17sx7i
30 Nov 23
Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update
7:05am